In the press

The latest news from Orange Grove Bio

 

January 31, 2024
Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science

Partnership represents firm’s second international collaboration and provides access to groundbreaking research taking place within world’s fifth largest pharmaceutical market The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, January 31, 2023 (GLOBE NEWSWIRE) – Orange Grove Bio, a drug investment and development firm, today announced that it has established a new

December 13, 2023
Thani Al Zeyoudi attends World Investment Forum to accelerate investment in high-potential markets

The following excerpt was taken from dailyhunt.me — continue reading here. ABU DHABI, 19th October, 2023 (WAM) – Dr Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, has held a series of high-level meetings with global ministers on the fourth day of the 8th World Investment Forum (WIF), during which he

November 10, 2023
Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology

OGB Also Announces Key Appointments to Board of Senior Advisors and the Opening of New Headquarters The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, Sept. 28, 2023 (GLOBE NEWSWIRE)  Orange Grove Bio (OGB), a drug investment and development firm, today announced that Preservation Bio, one of the firm’s majority-owned subsidiaries, has been

March 23, 2023
Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic Partnerships

Collaborations with Yonsei University Health System and Pohang University of Science and Technology Designed to Strengthen Biotech Entrepreneurial Ecosystem in South Korea The following excerpt was taken from Globenewswire– continue reading here. Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic Partnerships CINCINNATI, March 23, 2023 (GLOBE NEWSWIRE) — Orange Grove Bio, a

November 10, 2022
Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration

Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration to Strengthen Biotech Ecosystem and Support Development and Commercialization of Novel Therapeutics The following excerpt was taken from Globenewswire– continue reading here. Orange Grove Bio, a drug investment and development firm, today announced the establishment of a strategic collaboration with the Magnuson

July 5, 2022
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition

Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend

June 23, 2022
Orange Grove Bio Appoints Key Leadership & New Academic Collaboration

The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D. Orange Grove Bio, a preclinical drug investment and development

March 16, 2022
Orange Grove Bio and Cincinnati Children’s Hospital Medical Center Establish Collaboration

Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati

February 9, 2022
1819 Innovation Hub tenant inks key partnership with Korea VC firm

1819 Innovation Hub tenant inks key partnership with Korea VC firm The following excerpt was taken from TechOhio– continue reading here. A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration A biotech firm that moved its headquarters from New York to Cincinnati in

February 9, 2022
Leading Korean VC partners with USA’s Orange Grove

Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas.
Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.

November 17, 2021
New Partnership Continues Pitt’s Turn Toward Commercializing Research

New Partnership Continues Pitt’s Turn Toward Commercializing Research The following excerpt was taken from Pittsburgh Post-Gazette — continue reading here. An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies “An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies targeting

November 17, 2021
The University of Pittsburgh and Orange Grove Bio Establish Partnership …

The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration “Orange Grove Bio, a preclinical drug investment and development firm, and

November 17, 2021
Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine

Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth “Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration

November 4, 2021
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area

Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area The following excerpt was taken from Cincinnati Enquirer — continue reading here. Orange Grove Bio, a venture capital firm that invests mainly in therapeutic drug companies, is moving its headquarters from the New York City “Orange Grove Bio, a venture capital firm that invests

November 4, 2021
New York biotech firm moving HQ to Cincinnati

New York biotech firm moving HQ to Cincinnati The following excerpt was taken from Cincyinno Business Journal — continue reading here. A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819 Innovation Hub “A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819

October 6, 2021
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry

Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry We are excited to announce our portfolio company, Ipinovyxbio‘s, launch! The following was taken from Fierce Biotech–read it here or continue below! “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round” “Eli Lilly is among the

October 6, 2021
IpiNovyx Bio closes $10 million seed financing round

IpiNovyx Bio closes $10 million seed financing round The below is an excerpt taken from EndPoints News about our portfolio company, Ipinovyx Bio. The following excerpt was taken from EndPonts News — continue reading here. “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round “With a focus

October 6, 2021
IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform

IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform The following excerpt was taken from Trialsitenews — continue reading here. IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform “New York-based IpiNovyx Bio announced the closing of a $10 million seed financing round. The financing was led

March 9, 2021
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio

Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio The following was taken from PR Newswire and you can read it here: https://www.prnewswire.com/news-releases/research-bridge-partners-seed-capital-investment-in-asalyxa-bio-advances-dr-lola-eniola-adefesos-immune-cell-targeted-therapeutic-platform-301242853.html “Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Research Bridge Partners – a 501 (c) (3)

March 8, 2021
Cronicle Tech News

Cronicle Tech News The following was taken from the Cronicle written by Lauren K. Cowan. Check out the original piece here: https://cronicle.press/2021/03/08/ann-arbors-asalyxa-bio-raises-2-million-to-start-clinical-trials-for-neutrophil-targeting-drug-delivery-tech/ Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities Asalyxa Bio, Inc., a biopharmaceutical startup developing nano-engineered, immune cell-targeted therapeutics, just announced the closing of

February 25, 2021
Wall Street Journal

Wall Street Journal The following was taken from the Wall Street Journal. Check out the original piece here: https://www.wsj.com/articles/vc-daily-biotechs-test-new-company-building-model-11614261635 We are incredibly excited and humbled to be recognized in the Wall Street Journal for our innovative business model! We thank everyone who has been supporting us from the beginning. 

February 23, 2021
Asalyxa Bio Update

Asalyxa Bio Update The following excerpt was taken from PR Newswire — continue reading here. Asalyxa Bio, Inc., a biopharmaceutical company developing nano-engineered, immune cell-targeted therapeutics, today announced the closing of an over-subscribed seed financing round ANN ARBOR, Mich., Feb. 23, 2021 /PRNewswire/ — Asalyxa Bio, Inc., a biopharmaceutical company developing nano-engineered, immune cell-targeted therapeutics,

September 29, 2020
Our first portfolio company, Asalyxa Bio, has launched

Our first portfolio company, Asalyxa Bio, has launched. The University of Michigan, our partner in the creation of this company, released a press release which can be read below. — Asalyxa Bio, a startup with neutrophil targeting drug-delivery technology invented at University of Michigan Asalyxa Bio, a startup with neutrophil targeting drug-delivery technology invented at

May 11, 2020
New Podcast Launched

We are ecstatic to announce that we have launched our new podcast “OGB Podcast” on both Spotify and Anchor. We will be talking to industry leaders about the state of the biotech industry as well as delving into the specifics of our guests expertise. You can find and listen to us on Spotify ( https://open.spotify.com/show/0tSRtB4tFUcqHhW43RkWIL

April 26, 2020
Pre-clinical Biotech Development Opportunity Video

Pre-clinical Biotech Development Opportunity Video

April 11, 2020
Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST.

Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST. Please join us to hear from our CEO, Marc Appel.– continue reading here. Upcoming Webinar for Pre-Clinical Biotech Development Opportunities

January 31, 2020
Michigan BioSocial

Michigan BioSocial Upcoming Webinar for Pre-Clinical Biotech Development Opportunities

January 25, 2020
Orange Grove Bio: Filling the Gap in Preclinical Drug Development

Orange Grove Bio is a preclinical drug development company focused on driving down the cost of drug development… Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration Orange Grove Bio is a preclinical drug development company focused on driving down the cost

January 25, 2020
How to Invest in Biotech Series – Phases, Stages, and Pitfalls

Emily Whitehead was 5 years old when she was diagnosed with acute lymphoblastic leukemia… Her cancer was resistant to traditional treatments and her prognosis was poor. In a final effort to save their daughter, her parents enrolled her in a clinical trial study at Children’s Hospital of Philadelphia for a new type of therapy called

January 25, 2020
IF HENRY FORD WERE IN BIOTECH

IF HENRY FORD WERE IN BIOTECH Please join us to hear from our CEO, Marc Appel.